Literature DB >> 18953433

Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.

Patrick E Corsino1, Bradley J Davis, Peter H Nørgaard, Nicole N Teoh Parker, Mary Law, William Dunn, Brian K Law.   

Abstract

The basal-like subtype of breast cancer is associated with invasiveness, high rates of postsurgical recurrence, and poor prognosis. Aside from inactivation of the BRCA1 tumor-suppressor gene, little is known concerning the mechanisms that cause basal breast cancer or the mechanisms responsible for its invasiveness. Here, we show that the heterogeneous mouse mammary tumor virus-cyclin D1-Cdk2 (MMTV-D1K2) transgenic mouse mammary tumors contain regions of spindle-shaped cells expressing both luminal and myoepithelial markers. Cell lines cultured from these tumors exhibit the same luminal/myoepithelial mixed-lineage phenotype that is associated with human basal-like breast cancer and express a number of myoepithelial markers including cytokeratin 14, P-cadherin, alpha smooth muscle actin, and nestin. The MMTV-D1K2 tumor-derived cell lines form highly invasive tumors when injected into mouse mammary glands. Invasion is associated with E-cadherin localization to the cytoplasm or loss of E-cadherin expression. Cytoplasmic E-cadherin correlates with lack of colony formation in vitro and beta-catenin and p120(ctn) localization to the cytoplasm. The data suggest that the invasiveness of these cell lines results from a combination of factors including mislocalization of E-cadherin, beta-catenin, and p120(ctn) to the cytoplasm. Nestin expression and E-cadherin mislocalization were also observed in human basal-like breast cancer cell lines, suggesting that these results are relevant to human tumors. Together, these results suggest that abnormal Cdk2 activation may contribute to the formation of basal-like breast cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18953433      PMCID: PMC2570600          DOI: 10.1593/neo.08710

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  62 in total

1.  Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells.

Authors:  P C Wu; V C Lai; J W Fang; M A Gerber; C L Lai; J Y Lau
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

2.  Novel identification of zyxin upregulations in the motile phenotype of hepatocellular carcinoma.

Authors:  Shirley M-H Sy; Paul B-S Lai; Etonia Pang; Navy L-Y Wong; Ka-Fai To; Philip J Johnson; Nathalie Wong
Journal:  Mod Pathol       Date:  2006-05-05       Impact factor: 7.842

3.  Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.

Authors:  J M Schafer; E S Lee; R M O'Regan; K Yao; V C Jordan
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

4.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

5.  Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma.

Authors:  M Löhr; C Schmidt; J Ringel; M Kluth; P Müller; H Nizze; R Jesnowski
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

6.  Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.

Authors:  S G Brodie; X Xu; W Qiao; W M Li; L Cao; C X Deng
Journal:  Oncogene       Date:  2001-11-08       Impact factor: 9.867

Review 7.  BRCA1-associated tumorigenesis: what have we learned from knockout mice?

Authors:  S G Brodie; C X Deng
Journal:  Trends Genet       Date:  2001-10       Impact factor: 11.639

8.  Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.

Authors:  Zoë Weaver; Cristina Montagna; Xiaoling Xu; Tamara Howard; Massimo Gadina; Steven G Brodie; Chu-Xia Deng; Thomas Ried
Journal:  Oncogene       Date:  2002-08-01       Impact factor: 9.867

9.  The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node.

Authors:  Martin Lodén; Maria Stighall; Niels Hilmer Nielsen; Göran Roos; Stefan O Emdin; Hanna Ostlund; Göran Landberg
Journal:  Oncogene       Date:  2002-07-11       Impact factor: 9.867

Review 10.  Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  Breast Cancer Res       Date:  2001-11-30       Impact factor: 6.466

View more
  24 in total

1.  Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.

Authors:  Cheng-Chieh Yang; Adam LaBaff; Yongkun Wei; Lei Nie; Weiya Xia; Longfei Huo; Hirohito Yamaguchi; Yi-Hsin Hsu; Jennifer L Hsu; Dongping Liu; Jingyu Lang; Yi Du; Huang-Chun Lien; Long-Yuan Li; Rong Deng; Li-Chuan Chan; Jun Yao; Celina G Kleer; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

2.  HER2/ErbB2-induced breast cancer cell migration and invasion require p120 catenin activation of Rac1 and Cdc42.

Authors:  Emhonta Johnson; Darcie D Seachrist; Carlos M DeLeon-Rodriguez; Kristen L Lozada; John Miedler; Fadi W Abdul-Karim; Ruth A Keri
Journal:  J Biol Chem       Date:  2010-07-01       Impact factor: 5.157

3.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

4.  Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes.

Authors:  Stephan C Jahn; Mary E Law; Patrick E Corsino; Thomas C Rowe; Bradley J Davis; Brian K Law
Journal:  Biochemistry       Date:  2013-05-09       Impact factor: 3.162

5.  Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis.

Authors:  Dipankar Ray; Yasuhisa Terao; Konstantin Christov; Philipp Kaldis; Hiroaki Kiyokawa
Journal:  Neoplasia       Date:  2011-05       Impact factor: 5.715

6.  Constitutive Cdk2 activity promotes aneuploidy while altering the spindle assembly and tetraploidy checkpoints.

Authors:  Stephan C Jahn; Patrick E Corsino; Bradley J Davis; Mary E Law; Peter Nørgaard; Brian K Law
Journal:  J Cell Sci       Date:  2013-01-15       Impact factor: 5.285

7.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

8.  An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch.

Authors:  Stephan C Jahn; Mary E Law; Patrick E Corsino; Nicole N Parker; Kien Pham; Bradley J Davis; Jianrong Lu; Brian K Law
Journal:  Cancer Lett       Date:  2012-08-17       Impact factor: 8.679

9.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

10.  A novel role of EMMPRIN/CD147 in transformation of quiescent fibroblasts to cancer-associated fibroblasts by breast cancer cells.

Authors:  Jing Xu; Yang Lu; Songbo Qiu; Zhi-Nan Chen; Zhen Fan
Journal:  Cancer Lett       Date:  2013-03-06       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.